Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 4/2015

01-12-2015 | Metabolism (P Trayhurn, Section Editor)

The Influence of Bariatric Surgery on Serum Bile Acids in Humans and Potential Metabolic and Hormonal Implications: a Systematic Review

Authors: Abigail J. Cole, Levi M. Teigen, Cyrus Jahansouz, Carrie P. Earthman, Shalamar D. Sibley

Published in: Current Obesity Reports | Issue 4/2015

Login to get access

Abstract

Recent research suggests a mechanistic role for bile acids (BA) in the metabolic improvement following bariatric surgery. It is believed that the hormonal and metabolic effects associated with changes in systemic BAs may be related to the farnesoid X receptor (FXR) and a G-protein coupled receptor (TGR5). This systematic review examines changes in systemic BAs following bariatric procedures. Studies were included if they reported the measurement of systemic BAs in humans at at least one time point after bariatric surgery. Eleven papers were identified that met the inclusion criteria. Seven studies reported the effect of Roux-en-Y gastric bypass (RYGB) on fasting BAs. The majority (6/7) reported that fasting BAs increased after RYGB. Data regarding fasting BAs after vertical sleeve gastrectomy (VSG) and laparoscopic gastric banding (LAGB) are inconsistent. Data regarding post-prandial BA changes after RYGB, VSG, and LAGB are also inconsistent. More research is needed to investigate the connection between BAs and the metabolic improvement seen after bariatric surgery.
Appendix
Available only for authorised users
Literature
1.
Lutz TA, Bueter M. The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol. 2014;307:R1275–91.CrossRefPubMed
2.•
Goncalves D, Barataud A, De Vadder F, et al. Bile Routing modification reproduces key features of gastric bypass in rat. Ann Surg. 2015. This study shows that the benefits of RYGB in rats are related to bile routing modifications.
3.
Svane MS, Bojsen-Møller KN, Madsbad S, et al. Updates in weight loss surgery and gastrointestinal peptides. Curr Opin Endocrinol Diabet Obes. 2015;22:21–8.CrossRef
4.
Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32 Suppl 2:S237–45.PubMedCentralCrossRefPubMed
5.
Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–91.CrossRefPubMed
6.
7.
8.
Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep. 2014;14:482.CrossRefPubMed
9.
Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–5.CrossRefPubMed
10.
11.
Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–53.CrossRefPubMed
12.
Takeda S, Kadowaki S, Haga T, et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002;520:97–101.CrossRefPubMed
13.
Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435–40.CrossRefPubMed
14.
Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482–4.CrossRefPubMed
15.
Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-y gastric bypass. Diabetes Care. 2013;36:1859–64.PubMedCentralCrossRefPubMed
16.
Jansen PLM, Van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011;29:48–51.CrossRefPubMed
17.
Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg US. 2012;22:1473–80.CrossRef
18.
Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013;48:1257–64.CrossRefPubMed
19.
Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.PubMedCentralCrossRefPubMed
20.
Kohli R, Myronovych A, Xanthakos S, et al. Sleeve gastrectomy in mice and humans results in weight loss independent suppression of hepatic bile acid synthesis. Gastroenterology. 2013;S319–20.
21.
Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity. 2013;21:E660–8.CrossRefPubMed
22.
Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. Elsevier Inc.; 2009;58:1400–7.
23.•
Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183–8. This study provides evidence of a molecular mechanism involving FXR in the success of weight loss following VSG in mice.PubMedCentralCrossRefPubMed
24.
Bhutta HY, Rajpal N, White W, et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One. 2015;10:e0122273.PubMedCentralCrossRefPubMed
25.
Myronovych A, Kirby M, Seeley R, et al. Sleeve gastrectomy in obese mice results in elevated serum bile acids and reduced hepatic steatosis that correlate with weight loss post surgery. Gastroenterology. 2012;S13.
26.
Myronovych A, Kirby M, Ryan KK, et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity. 2014;22:390–400.PubMedCentralCrossRefPubMed
27.
Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633–71.CrossRefPubMed
28.
Chiang JYL. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40:539–51.CrossRefPubMed
29.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–74.CrossRefPubMed
30.
31.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedCentralCrossRefPubMed
32.
Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17:1671–7.CrossRefPubMed
33.
Haluzíková D, Lacinová Z, Kaválková P, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity. 2013;21:1335–42.CrossRefPubMed
34.
Ahmad N, Pfalzer A, Kaplan L. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. 2013;37:1553–9.CrossRef
35.
Dirksen C, Jørgensen N, Bojsen-Møller K, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes. 2013;37:1452–9.CrossRef
36.
Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98:E708–12.PubMedCentralCrossRefPubMed
37.
Mazuy C, Helleboid A, Staels B, et al. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol life Sci. 2014;1631–50.
38.
Cyphert HA, Ge X, Kohan AB, et al. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem. 2012;287:25123–38.PubMedCentralCrossRefPubMed
39.
Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143:1741–7.CrossRefPubMed
40.
Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594–603.CrossRefPubMed
41.
Hotta Y, Nakamura H, Konishi M, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009;150:4625–33.CrossRefPubMed
42.
43.
Zhang X, Yeung DCY, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246–53.CrossRefPubMed
44.
Woo YC, Xu A, Wang Y, et al. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 2013;78:489–96.CrossRef
45.
46.
47.
Watanabe M, Houten S, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484–9.CrossRefPubMed
48.
49.
50.
51.
Liou AP, Paziuk M, Luevano J-M, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:178ra41.PubMedCentralCrossRefPubMed
52.
Raghow R. Ménage-à-trois of bariatric surgery, bile acids and the gut microbiome. World J Diabet. 2015;6:367–70.CrossRef
53.
Lundåsen T, Gälman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med. 2006;260:530–6.CrossRefPubMed
54.
Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005;129:1445–53.CrossRefPubMed
55.
Everson GT. Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry. J Lipid Res. 1987;28:238–52.PubMed
Metadata
Title
The Influence of Bariatric Surgery on Serum Bile Acids in Humans and Potential Metabolic and Hormonal Implications: a Systematic Review
Authors
Abigail J. Cole
Levi M. Teigen
Cyrus Jahansouz
Carrie P. Earthman
Shalamar D. Sibley
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Obesity Reports / Issue 4/2015
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-015-0171-x

Other articles of this Issue 4/2015

Current Obesity Reports 4/2015 Go to the issue

Metabolism (P Trayhurn, Section Editor)

Recent Progress in the Understanding of Obesity: Contributions of Genome-Wide Association Studies

Economy and Environment (I Janssen, Section Editor)

Disability Discrimination and Obesity: The Big Questions?

Metabolism (P Trayhurn, Section Editor)

Horizons in the Pharmacotherapy of Obesity

Economy and Environment (I Janssen, Section Editor)

Beyond Physical Activity: The Importance of Play and Nature-Based Play Spaces for Children’s Health and Development

Health Services and Programs (SFL Kirk, Section Editor)

Innovations in the Use of Interactive Technology to Support Weight Management

Economy and Environment (I Janssen, Section Editor)

Playability: Built and Social Environment Features That Promote Physical Activity Within Children
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits